DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger — See source for full details.
$DMAC
Price history, market instrument context, member research, and related headlines in one place.
DMAC key statistics
NasdaqCMUSD
52-week range
$5.2554%$10.42
Latest session $7.70–$8.23DiaMedica Therapeutics Inc. (DMAC) is a stock instrument quoted on NasdaqCM in USD. The most recently published price is $8.04, up $0.38 (4.96%) from the previous close of $7.66. It has traded between $7.70 and $8.23 in the latest session. Over the past year it has ranged from $5.25 to $10.42, leaving it around the middle of its 52-week range (54%). Reported volume for the session was 303.9K. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance — See source for full details.
1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. 1 Main Capital Partners returned 15.0% in Q2 2026, compared to 15.2% and 21.6% for the S&P 500 (SPX) and Russell 2000 (RTY), respectively. SPX and RTY delivered their best performance since 2026 […]
Loading $DMAC research…